Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors: An international multicenter comparative study Journal Article


Authors: Fusai, G. K.; Tamburrino, D.; Partelli, S.; Lykoudis, P.; Pipan, P.; Di Salvo, F.; Beghdadi, N.; Dokmak, S.; Wiese, D.; Landoni, L.; Nessi, C.; Busch, O. R. C.; Napoli, N.; Jang, J. Y.; Kwon, W.; Del Chiaro, M.; Scandavini, C.; Abu-Awwad, M.; Armstrong, T.; Hilal, M. A.; Allen, P. J.; Javed, A.; Kjellman, M.; Sauvanet, A.; Bartsch, D. K.; Bassi, C.; van Dijkum, E. J. M. N.; Besselink, M. G.; Boggi, U.; Kim, S. W.; He, J.; Wolfgang, C. L.; Falconi, M.
Article Title: Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors: An international multicenter comparative study
Abstract: Background: The role of portal vein resection for pancreatic cancer is well established but not for pancreatic neuroendocrine neoplasms. Evidence from studies providing information on long-term outcome after venous resection in pancreatic neuroendocrine neoplasms patients is lacking. Methods: This is a multicenter retrospective cohort study comparing pancreaticoduodenectomy with vein resection with standard pancreaticoduodenectomy in patients with pancreatic neuroendocrine neoplasms. The primary endpoint was to evaluate the long-term survival in both groups. Progression-free survival and overall survival were calculated using the method of Kaplan and Meier, but a propensity score-matched cohort analysis was subsequently performed to remove selection bias and improve homogeneity. The secondary outcome was Clavien-Dindo ≥3. Results: Sixty-one (11%) patients underwent pancreaticoduodenectomy with vein resection and 480 patients pancreaticoduodenectomy. Five (1%) perioperative deaths were recorded in the pancreaticoduodenectomy group, and postoperative clinically relevant morbidity rates were similar in the 2 groups (pancreaticoduodenectomy with vein resection 48% vs pancreaticoduodenectomy 33%). In the initial survival analysis, pancreaticoduodenectomy with vein resection was associated with worse 3-year progression-free survival (48% pancreaticoduodenectomy with vein resection vs 83% pancreaticoduodenectomy; P < .01) and 5-year overall survival (67% pancreaticoduodenectomy with vein resection vs 91% pancreaticoduodenectomy). After propensity score matching, no significant difference was found in both 3-year progression-free survival (49% pancreaticoduodenectomy with vein resection vs 59% pancreaticoduodenectomy; P = .14) and 5-year overall survival (71% pancreaticoduodenectomy with vein resection vs 69% pancreaticoduodenectomy; P = .98). Conclusion: This study demonstrates no significant difference in perioperative risk with a similar overall survival between pancreaticoduodenectomy and pancreaticoduodenectomy with vein resection. Tumor involvement of the superior mesenteric/portal vein axis should not preclude surgical resection in patients with locally advanced pancreatic neuroendocrine neoplasms. © 2020 Elsevier Inc.
Journal Title: Surgery
Volume: 169
Issue: 5
ISSN: 0039-6060
Publisher: Elsevier Inc.  
Date Published: 2021-01-01
Start Page: 1093
End Page: 1101
Language: English
DOI: 10.1016/j.surg.2020.11.015
PUBMED: 33357999
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 1 June 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Peter Allen
    501 Allen